Menarini Silicon Biosystems: New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH CTC count in patients with metastatic breast cancer

Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with oestrogen

Related Keywords

China ,Italy ,Kostenloser Wertpapierhandel ,Fabio Piazzalunga ,Institut Curie ,Us Food Drug Administration ,China National Medical Products Administration ,Menarini Group ,Circulating Tumor Cell ,Silicon Biosystems ,Professor Francois Cl ,Antonio Breast Cancer Symposium ,Medical Oncology ,Breast Cancer ,Drug Administration ,Menarini Silicon ,Metastatic Breast ,Tumor Cell Test ,Huntingdon Valley ,Menarini Silicon Biosystems ,Circulating Tumor Cell Count Driven ,Clinician Driven First Line Therapy Choice ,Hormone Receptor Positive ,Negative Metastatic Breast Cancer ,Tumor Cells Driven ,Menarini ,Ilicon ,Kbiosystems ,Tic ,Trial ,Data ,Shows ,Longer ,Verall ,Survival ,Therapy ,Election ,Ased ,Ellsearch ,Count ,Patients ,Metastatic ,Breast ,Dancer ,